// App-Quantinova.ai

4092 : A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC).

Researchers

Presenter

  • Andrea Cercek

Principal Investigators

  • Thomas Boerner

  • Benjamin R. Tan

  • Joanne F. Chou

  • Mithat Gonen

  • Taryn Mary Boucher

  • Haley Hauser

  • Richard K. G. Do

  • Maeve Aine Lowery

  • Peter Kingham

  • Michael Ian D'Angelica

  • Jeffrey A. Drebin

  • Peter J. Allen

  • Neeta Vachharajani

  • Maria Majella Doyle

  • Ryan Fields

  • William G. Hawkins

  • William C. Chapman

  • William R. Jarnagin

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Washington University School of Medicine, St. Louis, MO

  • University of Pennsylvania, Philadelphia, PA

  • Washington University, St Louis, MO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Gemcitabine

  • floxuridine

  • Oxaliplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01862315

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved